News

Toyota Suspends Sichuan Plant Operation Due to Power Shortage

-Reuters Citing Kyodo

byCharles Gross

August 16, 2022

1 minute read

-Reuters Citing Kyodo

Only 2 Months Until This Jobs Measure Screams Worry, Economist Says

By Adam Eckert

Today, 2:42 AM

American economist Paul Krugman has warned that the economy may be turning faster than most think and the Federal Reserve may have overshot in its aggressive response to rising inflation.

SPY

Biomerica Announces Topline Results From The Endpoint Clinical Trial Of Its InFoods IBS Treatment For Patients With Irritable Bowel Syndrome; Co. Reported ‘Multiple endpoints demonstrated statistically significant improvements’

By Benzinga Newsdesk

Today, 2:42 AM

InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind using science, diet and technology to identify patient specific foods, which when eliminated, help reduce the symptoms of IBS

BMRA

5 Stocks Insiders Are Selling

By Lisa Levin

Today, 2:42 AM

When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.

AEO

Morgan Stanley Upgrades argenx to Overweight, Announces $375 Price Target

By Benzinga Newsdesk

Today, 2:42 AM

Morgan Stanley analyst Matthew Harrison upgrades argenx (NASDAQ:ARGX) from Equal-Weight to Overweight and announces $375 price target.

ARGX

Toyota Suspends Sichuan Plant Operation Due to Power Shortage

Related Posts

Only 2 Months Until This Jobs Measure Screams Worry, Economist Says

Biomerica Announces Topline Results From The Endpoint Clinical Trial Of Its InFoods IBS Treatment For Patients With Irritable Bowel Syndrome; Co. Reported ‘Multiple endpoints demonstrated statistically significant improvements’

5 Stocks Insiders Are Selling

Morgan Stanley Upgrades argenx to Overweight, Announces $375 Price Target